3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
4
Rituximab
3
cobomarsen
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
thymoglobulin
1
ponatinib
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
fludarabine
1
Vorinostat
1
Tacrolimus
1
Mycophenolic Acid
1
Melphalan
1
Imatinib Mesylate
1
Ifosfamide
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Busulfan
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Immune System Diseases
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled